A trial postmortem: challenges in conducting a randomized, double-blind, phase 2 study in men with castration-resistant prostate cancer

Eur Urol. 2012 Nov;62(5):864-6. doi: 10.1016/j.eururo.2012.08.030. Epub 2012 Aug 25.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Editorial
  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Advertising
  • Antineoplastic Agents, Hormonal / adverse effects
  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Castration*
  • Double-Blind Method
  • Early Termination of Clinical Trials
  • Health Knowledge, Attitudes, Practice
  • Humans
  • Kallikreins / blood
  • Male
  • Patient Education as Topic
  • Patient Selection
  • Prostate-Specific Antigen / blood
  • Prostatic Neoplasms / blood
  • Prostatic Neoplasms / drug therapy*
  • Prostatic Neoplasms / pathology
  • Research Design*
  • Testosterone / adverse effects
  • Testosterone / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Testosterone
  • Kallikreins
  • kallikrein-related peptidase 3, human
  • Prostate-Specific Antigen

Associated data

  • ClinicalTrials.gov/NCT00515112